Your browser doesn't support javascript.
Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020.
Harvala, Heli; Mehew, Jennifer; Robb, Matthew L; Ijaz, Samreen; Dicks, Steven; Patel, Monika; Watkins, Nicholas; Simmonds, Peter; Brooks, Tim; Johnson, Rachel; Gopal, Robin; Roberts, David J; Zambon, Maria.
  • Harvala H; Microbiology Services, NHS Blood and Transplant, London, United Kingdom.
  • Mehew J; Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom.
  • Robb ML; Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom.
  • Ijaz S; Virology Reference Department, National Infection Service, Public Health England, Colindale Avenue, London, United Kingdom.
  • Dicks S; Microbiology Services, NHS Blood and Transplant, London, United Kingdom.
  • Patel M; Virology Reference Department, National Infection Service, Public Health England, Colindale Avenue, London, United Kingdom.
  • Watkins N; High Containment Microbiology, National Infection Service, Public Health England, Colindale Avenue, London, United Kingdom.
  • Simmonds P; NHS Blood and Transplant, Cambridge, United Kingdom.
  • Brooks T; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Johnson R; Rare & Imported Pathogens Laboratory, Public Health England, Porton Down, United Kingdom.
  • Gopal R; Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom.
  • Roberts DJ; High Containment Microbiology, National Infection Service, Public Health England, Colindale Avenue, London, United Kingdom.
  • Zambon M; Radcliffe Department of Medicine and BRC Haematology Theme, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
Euro Surveill ; 25(28)2020 Jul.
Article in English | MEDLINE | ID: covidwho-647502
ABSTRACT
Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Antibodies, Neutralizing / Betacoronavirus Type of study: Diagnostic study / Prognostic study Limits: Adolescent / Adult / Aged / Humans / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal subject: Communicable Diseases Year: 2020 Document Type: Article Affiliation country: 1560-7917.ES.2020.25.28.2001260

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Antibodies, Neutralizing / Betacoronavirus Type of study: Diagnostic study / Prognostic study Limits: Adolescent / Adult / Aged / Humans / Middle aged / Young adult Country/Region as subject: Europa Language: English Journal subject: Communicable Diseases Year: 2020 Document Type: Article Affiliation country: 1560-7917.ES.2020.25.28.2001260